Clinical trials: PET/CT
Primary Hyperparathyroidism
18F-choline Positron-emission-tomography - Computed-tomography Compared to Conventional Imaging for Localizing Diseased Parathyroid Glands in Primary Hyperparathyroidism
The goal of this open, single-center, prospective, randomized, clinical study is to compare imaging with [18F]fluoromethyl-dimethyl-2-hydroxyethylammonium (18F-choline) positron-emission-tomography - computed-tomography…
- Trial name
- NCT07138820
- Testing
- Parathyroidectomy
- Where
- Sweden
- Volunteers
- 88 people
- Sponsor
- Region Skane
Glioma, Astrocytoma
Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas
As a part of molecular imaging, many PET tracers have been investigated in this regard. Those include 18F-FDG being glucose analogue, 18F-FLT representing nucleoside metabolism, and 18F-FDOPA, 18F-FET, 11C-MET as amino acids…
- Conditions
- Glioma, Astrocytoma, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT06241391
- Testing
- PSMA PET-CT
- Where
- India
- Volunteers
- 35 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Head and Neck Squamous Cell Carcinoma
Liquid Biopsy in Head and Neck Cancer
Overall survival of patients with head and neck squamous cell carcinoma (HNSCC) remains unsatisfactory due to often advanced clinical stage at diagnosis and high rate of recurrence and second primaries.
- Trial name
- NCT03926468
- Testing
- Liquid biopsy
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Turku University Hospital
Colorectal Cancer
FAPI PET/CT for Lymph Node Staging in Colorectal Carcinoma
To describe the accuracy of FAPI PET/CT in the detection of regional lymph node metastases in patients with colorectal cancer in comparison with standard diagnostic imaging and (in operated patients) histopathology, aiming to…
- Trial name
- FAPI-CRC1 (NCT05209750)
- Testing
- FAPI PET/CT
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- The Netherlands Cancer Institute
Aging, Inflammation
Relationship Between Thoracic Aortic Structure Assessed B PET/CT Scan and Arterial Stiffness in Elderly Patients
The purpose of this study is to determine the relationship between thoracic aortic inflammation and arterial stiffness in elderly patients.
- Trial name
- FICTEP (NCT01963221)
- Testing
- fludeoxyglucose(18f), blood sample, cardiac and aortic magnetic resonance imaging
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Urinary Bladder Neoplasms
uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer
The sensitivity and specificity of uPAR PET/CT with the radioligand 68GaNOTA-AE105 and FDG PET/MRI for preoperative detection of regional lymph node metastases in urinary bladder cancer
- Trial name
- NCT02805608
- Testing
- Injection of 68Ga-NOTA-AE105, Injection of 18F-FDG, Positron Emission Tomography and CT
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
Having bacteria in the blood can be very dangerous. This is called bacteraemia (or bacteremia) or bloodstream infection. It can lead to problems across the whole body, which is what happens in sepsis.
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Sepsis Bacterial, Bloodstream Infection
- Trial name
- PET-SAB (NCT05361135)
- Testing
- PET/CT
- Volunteers
- 820 people
- Sponsor
- University College, London
sRAGE Level, SUV and TBR Levels in FDG PET
Association Between Arterial Wall Uptake of Fluorodeoxyglucose on PET Imaging and sRAGE
Arteriosclerosis is a dynamic inflammatory disorder. Recently, FDG-PET CT is emerging diagnostic tool of non-invasive technique to detect vulnerable atherosclerotic plaque.
- Trial name
- NCT01021514
- Volunteers
- 82 people
- Sponsor
- Korea University
Prostate Cancer, Prostatic Neoplasm
Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed
This is a diagnostic accuracy prospective, single-centre, open-label, single group assignment interventional study. Its aim is to evaluate the diagnostic accuracy of [68Ga]Ga-PSMA-11 PET/CT in detection of primary tumour and…
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Urogenital Neoplasms, Prostatic Disease
- Trial name
- PSMA-PROSTAPET (NCT04462926)
- Testing
- [68Ga]Ga-PSMA-11 PET/CT
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Oncology
Demonstration Of A Next Generation PET CT System
The intent of this evaluation is to obtain user feedback on device performance, user preference, image quality, workflow, and new device features, a necessary part of product development.
- Trial name
- NCT05122715
- Testing
- Additional PET/CT Scan
- Where
- Israel
- Volunteers
- 70 people
- Sponsor
- GE Healthcare
Bladder Cancer
Early Versus Late FDG-PET/CT in Bladder Cancer
The aim of this study is to examine if late FDG-PET/CT images after intravenous FDG injection has a higher sensitivity and specificity in detecting local lymph node metastases in patients with muscle invasive BC than FDG-PET/CT…
- Trial name
- NCT03065725
- Testing
- late FDG
- Where
- 2 sites in Denmark
- Volunteers
- 179 people
- Sponsor
- Jørgen Bjerggaard Jensen
Surgically Staged Endometrial and Cervical Carcinoma, Cervical Cancer: Invasive Disease, FIGO Stage 1B1 or Higher
Diagnostic Accuracy of MRI, DWI MRI, FDG-PET/CT and FEC PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma
This is a prospective diagnostic performance study which compares three new imaging methods with the current standard imaging method for the diagnosis of metastatic lymph nodes.
- Conditions
- Surgically Staged Endometrial and Cervical Carcinoma, Cervical Cancer: Invasive Disease, FIGO Stage 1B1 or Higher, Endometrial Cancer, Stage 1A With Myometrial Invasion or Any Higher Stage and Grade 3
- Trial name
- MAPPING (NCT01836484)
- Testing
- Diffusion-weighted MRI, Fluorodeoxyglucose-18-PET/CT, Fluoro-ethyl-coline-PET/CT
- Where
- 7 sites in United Kingdom
- Volunteers
- 162 people
- Sponsor
- Barts & The London NHS Trust
Diffuse Large B-cell-lymphoma, Classical Hodgkin Lymphoma
Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma
According to the most recent guidelines, total-body imaging techniques are an indispensable element in the staging and post-treatment re-evaluation in patients with lymphoma.
- Trial name
- NCT03042247
- Testing
- FDG PET/TC and FDG PET/MRI
- Where
- 2 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Marco Picardi
PET/CT, COVID-19
Study for Quantitative Analysis of the Recovered COVID-19 Patients by 18F-FDG-PET/CT
In this study, clinically cured patients with severe COVID-19 were used to evaluate the therapeutic effect of COVID-19 and the recovery and health status of patients over time with highly sensitive PET/CT imaging technology.
- Conditions
- PET/CT, COVID-19, Respiratory Function, Inflammatory Lesions
- Trial name
- NCT04519255
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Adult Medulloblastoma, Childhood Medulloblastoma
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with…
- Conditions
- Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma, Neuroendocrine Tumor
- Trial name
- NCT01869725
- Testing
- gallium Ga 68-edotreotide, positron emission tomography/computed tomography, indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Sue O'Dorisio
Prostate Cancer
68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can show prostate cancer on a PET/CT scan.
- Trial name
- NCT02559115
- Testing
- 68Ga-RM2 (RM2), PET/CT Scan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Lung Cancer
Intra-individual Comparison of Conventional and Digital PET/CT Scanners
In this study, the investigators will analyze the impact of digital PET/CT on the final diagnostic conclusion of the scan in patients with lung cancer, breast cancer, esophageal cancer and a group of mescellaneous cancers.
- Conditions
- Breast Cancer, Lung Cancer, Esophageal Cancer, Miscellaneous Neoplasm
- Trial name
- NCT03457506
- Testing
- Digital PET/CT scan
- Where
- Netherlands
- Volunteers
- 225 people
- Sponsor
- Isala
Lung Cancer, Lung Tuberculosis
68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT
Comparison of 68Ga-AlfatideII and 18F-FDG in differential diagnosis effectiveness towards the solitary pulmonary nodules of lung cancer or tuberculosis.
- Trial name
- NCT02481726
- Testing
- 68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Metastatic Sarcoma, Esophageal Cancer
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to…
- Conditions
- Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- PHANTOM (NCT06298916)
- Testing
- 64Cu-LNTH-1363S
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Lantheus Medical Imaging
Anal Cancer
Individual Following in Anal Cancer With PET/CT
Anal canal cancer is a relatively rare disease, representing 1.2% of digestive cancers and 6% of anorectal cancers. Incidence is less than 1/100 000 of the general population.
- Trial name
- IFACT (NCT02697084)
- Testing
- anal cancer
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Centre Antoine Lacassagne